NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Vancouver, Canada, May 7, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announces the results of its Annual General Meeting of Shareholders (“AGM”) held on May 6, 2025. The company reports that at the AGM […]
NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, Canada, April 21, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, ON. Mike Kelly, President & CEO, is scheduled to present at the conference on Monday, May 5, […]
NervGen Provides Quarterly “At-The-Market” Equity Program Update
Vancouver, British Columbia, April 9, 2025 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today provided a quarterly update with respect to the Company’s previously announced at-the-market equity program (the “ATM Program”) launched on December 19, 2024. The ATM Program allows the […]
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates
Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for lead drug candidate, NVG-291, in spinal cord injury (SCI) Initiated an expanded access protocol for NVG-291 for individuals with SCI who have participated in a NervGen clinical trial and meet specific eligibility criteria Pipeline candidate […]
NervGen Initiates Expanded Access Policy
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceed This news release constitutes a “designated news release” for the purposes of NervGen’s prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024. VANCOUVER, Canada, March 31, 2025 […]
NervGen Pharma to Host Virtual Investor Event
Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen’s Phase 1b/2a clinical trial evaluating NVG-291 in individuals with spinal cord injury Vancouver, Canada, March 25, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. March 14, 2025 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 545,000 incentive stock options (the “Options”) to employees and consultants of the company, including 100,000 to the company’s officers and 15,000 to consultants providing investor relations services. […]
NervGen Pharma to Present at the Virtual Life Science Investor Forum
Vancouver, Canada, March 5, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be presenting at the Virtual Life Sciences Investor Forum hosted by OTC Markets Group and VirtualInvestorConferences.com, on Thursday, March 13, 2025, at 12:00 […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. February 18, 2025 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 627,200 incentive stock options to the company’s employees, including 505,200 to the company’s Officers, exercisable at a price of $2.97 per share for a period of 10 […]
NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
VANCOUVER, Canada, February 6, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) evaluating its lead candidate, NVG-291, in individuals […]